TABLE 2.
Seroconversion
| Group and cat no. | Binding of sera to viral components as a function of
time after challengea
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| SU2
|
TM2
|
p24
|
|||||||
| 3 wk | 4 wk | 5 wk | 3 wk | 4 wk | 5 wk | 3 wk | 4 wk | 5 wk | |
| SU2 | |||||||||
| 324 | —b | — | — | 0 | 2.1 | 2.5 | 0 | 0.2 | 1.9 |
| 325 | — | — | — | 0 | 1.4 | 2.1 | 0 | 0 | 0.2 |
| 326 | — | — | — | 0 | 1.3 | 2.1 | 0 | 0.2 | 1.1 |
| 327 | — | — | — | 0 | 2.2 | 2.3 | 0 | 0.4 | 1.3 |
| SU5 | |||||||||
| 328 | 0 | 1.9 | 2.4 | 2.3 | 2.9 | 3.0 | 0.1 | 2.7 | 2.9 |
| 329 | 0 | 0.5 | 0.7 | 0 | 2.8 | 3.1 | 0 | 1.0 | 2.2 |
| 340 | 0 | 0 | 0.1 | 0.1 | 2.4 | 2.8 | 0 | 0.2 | 0.8 |
| 341 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TM3 | |||||||||
| 346 | 0 | 0 | 0 | 0 | 0.1 | 1.9 | 0 | 0.1 | 0.6 |
| 347 | 0 | 0 | 0 | 1.2 | 2.4 | 2.5 | 0.2 | 2.3 | 2.3 |
| 348 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 349 | 0 | 0 | 0 | 0 | 0.5 | 2.3 | 0.1 | 0 | 0.1 |
| Adjuvant | |||||||||
| 354 | 0 | 2.4 | 3.0 | 0 | 2.6 | 3.0 | 0 | 0 | 2.6 |
| 355 | 0 | 0.2 | 0.2 | 0.1 | 2.3 | 3.1 | 0 | 0.1 | 2.0 |
| 356 | 0.4 | 0.3 | 0.3 | 2.2 | 3.0 | 3.1 | 0 | 0.5 | 1.4 |
| 357 | 0 | 0.2 | 1.0 | 0.2 | 2.9 | 3.1 | 0.1 | 0.9 | 2.5 |
a
Data were obtained by ELISA on envelope peptides SU2 and TM2 and on recombinant FIV capsid protein (p24) for serum dilutions of 1/25 (peptides) and 1/100 (p24) and are expressed as optical density as described in Materials and Methods.
b
—, Data not shown for the group of cats vaccinated with the SU2 peptide and thus seropositive prior to challenge.